Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties. It acts as a positive allosteric modulator of GABA$_A$ receptors, enhancing inhibitory neurotransmission.
## Primary Indications
* Adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.
* Off-label uses include other seizure types and adjunctive therapy in certain movement disorders.
## Adult Dosing
* **Lennox-Gastaut Syndrome:** Initial dose is typically 5 mg twice daily. Dosage can be increased by 5-10 mg/day every week. The usual maintenance dose is 10-20 mg twice daily. Maximum recommended dose is 20 mg twice daily.
## Pediatric Dosing
* **Lennox-Gastaut Syndrome (2 to less than 10 years of age):** Initial dose is typically 2.5 mg twice daily. Dosage can be increased by 2.5-5 mg/day every week. The usual maintenance dose is 5 mg twice daily. Maximum recommended dose is 10 mg twice daily.
* **Lennox-Gastaut Syndrome (10 years of age and older):** Dosing is the same as for adults, with a maximum recommended dose of 20 mg twice daily.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dosing adjustments are established, but lower doses may be warranted due to potential for increased systemic exposure.
* **Renal Impairment:** Use with caution. No specific dosing adjustments are established.
## Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe respiratory impairment.
* Severe hepatic impairment.
## Adverse Effects
Common adverse effects include somnolence, increased appetite, constipation, aggression, irritability, difficulty with coordination, and upper respiratory tract infections. Serious adverse effects can include severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), suicidal behavior or ideation, and withdrawal symptoms upon abrupt discontinuation.
## Key Drug Interactions
* **CNS Depressants:** Additive effects with alcohol, opioids, other benzodiazepines, sedatives, and hypnotics can lead to profound sedation, respiratory depression, coma, and death.
* **CYP2C19 Inhibitors/Inducers:** Clobazam is a substrate of CYP2C19. Strong inhibitors (e.g., fluconazole) may increase clobazam levels, and strong inducers (e.g., rifampin) may decrease levels.
* **Stimulants:** May reduce the efficacy of stimulants.
## Monitoring
* Monitor for therapeutic effectiveness and adverse effects, especially somnolence, behavioral changes, and signs of skin reactions.
* Monitor for signs of withdrawal if discontinuation is considered.
* Monitor for potential drug interactions, especially with concomitant CNS depressants.
## Clinical Pearls
* Clobazam has a longer half-life compared to many other benzodiazepines, which may allow for less frequent dosing in some cases.
* Abrupt discontinuation can lead to withdrawal symptoms, including rebound seizures. Tapering is recommended.
* Due to the risk of severe skin reactions, patients should be advised to seek immediate medical attention if a rash develops.
***
*Disclaimer: This information is intended for healthcare professionals and does not substitute for professional medical advice. Always consult the most current prescribing information and relevant clinical guidelines before making any treatment decisions.*
